Norvir

RSS

ritonavir

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Norvir. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Norvir.

This EPAR was last updated on 21/11/2018

Authorisation details

Product details
Name
Norvir
Agency product number
EMEA/H/C/000127
Active substance
ritonavir
International non-proprietary name (INN) or common name
ritonavir
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AE03
Publication details
Marketing-authorisation holder
AbbVie Deutschland GmbH Co. KG
Revision
60
Date of issue of marketing authorisation valid throughout the European Union
25/08/1996
Contact address
Knollstrasse
67061 Ludwigshafen
Germany

Product information

13/09/2018 Norvir - EMEA/H/C/000127 - WS/1411/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older).

Assessment history

How useful was this page?

Add your rating
Average
1 rating